文献速递肝病

非酒精性脂肪性肝病进展至肝硬化及肝硬化进展至失代偿和死亡率的真实世界医疗保险数据分析

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-05

基于2007至2015年20%医疗保险代表性样本的回顾性分析,评估621253例确诊非酒精性脂肪性肝病(NAFLD)患者。随访8年,NAFLD进展至肝硬化累积风险39%,代偿性肝硬化进展至失代偿45%;NAFLD、NAFLD肝硬化、失代偿性肝硬化和肝细胞癌的累积死亡风险分别为12.6%、31.1%、51.4%和76.2%。

要点

  • NAFLD患者中71.1%为单纯NAFLD/非酒精性脂肪性肝炎,28.9%为NAFLD肝硬化。
  • 随访8年,NAFLD进展至肝硬化累积风险39%,代偿性肝硬化进展至失代偿45%。
  • 心血管疾病、肾功能损害、血脂异常和糖尿病是疾病进展的独立预测因素。

核心结论

  • NAFLD在真实临床环境中被严重诊断不足。
  • 该报告提供了NAFLD进展率及不同严重程度NAFLD和肝硬化中死亡风险因素的新证据。

研究设计与样本

  • 回顾性分析2007年至2015年20%医疗保险代表性样本的理赔数据。
  • 共评估10,826,456例患者,NAFLD患病率5.7%(N=621,253)。
  • 成人按疾病严重程度分组:单纯NAFLD/非酒精性脂肪性肝炎(NASH)、代偿性肝硬化、失代偿性肝硬化、肝移植或肝细胞癌。
  • 计算各组死亡和疾病进展的累积发生率,并进行多因素分析,调整人口学特征、合并症和疾病严重程度。

主要发现

  • NAFLD患者中71.1%为单纯NAFLD/NASH,28.9%为NAFLD肝硬化。
  • 总体中85.5%有高血压,84.1%有血脂异常,68.7%有心血管疾病,55.5%有糖尿病。
  • 随访8年,NAFLD进展至肝硬化的累积风险为39%,代偿性肝硬化进展至失代偿性肝硬化为45%。
  • 疾病进展的独立预测因素包括心血管疾病、肾功能损害、血脂异常和糖尿病。
  • NAFLD、NAFLD肝硬化、失代偿性肝硬化和肝细胞癌的累积死亡风险分别为12.6%、31.1%、51.4%和76.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk factors and timing associated with disease progression and mortality in nonalcoholic fatty liver disease (NAFLD) are poorly understood. AIMS: To evaluate the impact of disease severity, demographics and comorbidities on risk of mortality and time to progression in a large, real-world cohort of diagnosed NAFLD patients. METHODS: Claims data from a 20% Medicare representative sample between 2007 and 2015 were analysed retrospectively. Adults were categorised into disease severity groups: NAFLD/nonalcoholic steatohepatitis (NASH) alone, compensated cirrhosis, decompensated cirrhosis, liver transplant or hepatocellular carcinoma. Cumulative incidence of mortality and disease progression were calculated for each group and multivariate analyses performed adjusting for demographics, comorbidities and disease severity. RESULTS: A total of 10 826 456, patients were assessed and the prevalence of NAFLD was 5.7% (N = 621 253). Among patients with NAFLD, 71.1% had NAFLD/NASH alone and 28.9% had NAFLD cirrhosis. Overall, 85.5% of patients had hypertension, 84.1% dyslipidemia, 68.7% had cardiovascular disease and 55.5% diabetes. The cumulative risk of progression of NAFLD to cirrhosis, and compensated cirrhosis to decompensated cirrhosis was 39% and 45%, respectively, over 8 years of follow-up. The independent predictors of progression included cardiovascular disease, renal impairment, dyslipidemia and diabetes. The cumulative risk of mortality for NAFLD, NAFLD cirrhosis, decompensated cirrhosis and hepatocellular carcinoma was 12.6%, 31.1%, 51.4% and 76.2%, respectively. CONCLUSIONS: The present report (a) demonstrates that NAFLD is grossly underdiagnosed in real-world clinical settings and (b) provides new evidence on the progression rates of NAFLD and risk factors of mortality across the spectrum of severity of NAFLD and cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020. PMID: 32372515. doi:10.1111/apt.15679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。